Intellia plots pivotal trials for lead programs as it lays out key objectives
Intellia has some big plans for the next two years, including pivotal trials for its first two in vivo CRISPR therapies.
The Cambridge, MA-based genome editing company on Thursday disclosed its game plan for 2023 and 2024, starting with INDs for the inclusion of US sites in studies for NTLA-2001 and NTLA-2002 in transthyretin (ATTR) amyloidosis with cardiomyopathy and hereditary angioedema (HAE), respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.